NEW
BRUNSWICK, N.J., June 8, 2022
/PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today published
its 2021 Health for Humanity Report, which shares progress
against its purpose-driven Health for Humanity 2025 Goals and
serves as its annual disclosure on environmental, social and
governance (ESG) performance. In year one, we have exceeded one
Health for Humanity 2025 Goal and are on track to deliver against
the remaining 20 goals.
"Events from the past two years have only reinforced our
understanding of the critical importance of good health,"
said Joaquin Duato, Chief Executive Officer, Johnson &
Johnson. "During these extraordinary times, we held tight to our
values, kept patients at the center of everything we do and never
lost sight of Our Purpose to advance health. Driven by our Health
for Humanity 2025 Goals, our 144,000 employees helped to improve
health outcomes for patients and healthcare providers; to nurture a
culture that embraces diversity, promotes equity and fosters
inclusion; and to strengthen the communities in which we live and
work."
In 2021, we continued to focus on solving challenging global
health issues that align with our ESG strategic priorities. Built
on a foundation of accountability and innovation, these strategic
priorities – championing global health equity, empowering our
employees and advancing environmental health – guided how we worked
to create value for the stakeholders we serve. Highlights from the
2021 Report include:
Championing global health equity
We fostered better health for people, communities and the
planet, improving access and affordability around the world:
- Continued our long-standing commitment to address diseases that
disproportionately impact some of the world's most underserved
communities, including tuberculosis and HIV, and to apply our
expertise and partnering power to expand global equitable access to
our company's portfolio of medicines and health technologies
- Donated > 2 billion doses of VERMOX since
2006 to facilitate treatment of intestinal worms
- Provided 731,000 nurses, midwives and community health
workers with skills, tools and growth opportunities*
- Invested in culturally competent community care models to close
racial health gaps, reaching 159,000 healthcare
professionals and researchers in the U.S. as part of Our Race to
Health Equity platform, a $100
million five-year U.S. commitment to help eradicate racial
and social injustice as a public health threat*
- Supported 3,200 fistula repair surgeries through suture
donations in 17 countries
Empowering our employees
We cultivated a workforce that is healthy, inspired and
reflective of those we serve:
- Refreshed our Enterprise diversity, equity and inclusion
strategy, and increased global representation of women and ethnic,
racially diverse employees at all levels of our business while
reinforcing a culture of inclusion and belonging
- Recommended as a great place to work by 87% of employees
Advancing environmental health
We protected environmental health and the resilience of our
business:
- Reduced global CO2e emissions (Scope 1 and
Scope 2) by 34% since 2016
- Signed the Race to Zero/Business Ambition for 1.5°C
campaign, aiming to achieve net zero carbon emissions by
2045
Accountability & innovation
We are committed to science and data-driven decision making,
compliance, integrity and responsible business practices across the
value chain:
- Spent $5.22 billion with
small and diverse suppliers, exceeding our Health for Humanity 2025
Goal in year one
- Increased our R&D spend to $14.7
billion, the highest annual spend in our recent history
Reporting Frameworks and Standards
- The 2021 Report has been prepared in accordance with the Global
Reporting Initiative (GRI) Standards: Core option, and we report
our performance against GRI's Culture of Health for Business
(COH4B) framework.
- The 2021 Report includes the Sustainability Accounting
Standards Board (SASB) Index, providing disclosures against
relevant SASB Standards and Task Force on Climate-related Financial
Disclosures (TCFD), building on Johnson & Johnson's responses
to the CDP climate questionnaire in previous years.
- New in the 2021 Report, we've added Norges Bank Investment
Management and Basel Institute on Governance's "Measuring
effectiveness of anti-corruption programmes" reporting framework,
augmenting disclosures against this set of 17 indicators.
- The 2021 Report also serves as our annual United Nations Global
Compact Communication on Progress.
"As the most broadly based healthcare company, our commitment to
creating a healthier society is foundational to our business," said
Joseph J. Wolk, Executive Vice
President, Chief Financial Officer, Johnson & Johnson. "How we
deliver meaningful impact to human health is correlated with
generating long-term business results, which are complementary to
ESG actions that create accountability and value."
Johnson & Johnson will hold an ESG Investor Update Webcast
featuring Joaquin Duato;
Joseph J. Wolk; Peter Fasolo, Executive Vice President, Chief
Human Resources Officer, Johnson & Johnson; three members of
the Johnson & Johnson Board of
Directors and leaders from across the Enterprise on June 21,
2022 at 8:30 a.m. ET to outline its progress and
performance related to its ESG strategy, including highlights from
the 2021 Report. Investors and other interested parties can
pre-register for the webcast by
visiting: https://investor.jnj.com/esg-update.
* Funded in part by the Johnson & Johnson Foundation, a
registered charity and a company limited by guarantee, and by the
Corporation and operating companies across the Johnson &
Johnson Family of Companies. The Foundation operates worldwide as
Johnson & Johnson Foundation US (founded 1953) and Johnson
& Johnson Foundation Scotland (founded 2007).
Johnson & Johnson Environmental, Social and Governance
(ESG)
At Johnson & Johnson (NYSE:JNJ), we're driven by Our
Purpose to change the trajectory of health for humanity. Our ESG
strategy focuses our efforts on the areas where we are uniquely
positioned to achieve the greatest impact – championing global
health equity, empowering our employees and advancing environmental
health – and builds on a foundation of accountability and
innovation. We create long-term value by helping to achieve better
health outcomes for patients and healthcare providers, foster
rewarding opportunities for our employees and suppliers, protect
and strengthen the communities in which we live and work, and
provide profitable, sustainable growth for investors. Our Health
for Humanity 2025 Goals align to our ESG strategy, support 11
of the 17 United Nations Sustainable Development Goals and are how
we hold ourselves publicly accountable. Read more about our
progress in our Health for Humanity Report.
About Johnson & Johnson
At Johnson & Johnson, we believe good health is the
foundation of vibrant lives, thriving communities and forward
progress. That's why for more than 130 years, we have aimed to keep
people well at every age and every stage of life. Today, as the
world's largest and most broadly-based healthcare company, we are
committed to using our reach and size for good. We strive to
improve access and affordability, create healthier communities, and
put a healthy mind, body and environment within reach of everyone,
everywhere. We are blending our heart, science and ingenuity to
profoundly change the trajectory of health for humanity. Learn more
at www.jnj.com. Follow us at @JNJNews.
Forward-looking Statements
This press release contains "forward-looking statements" as
defined in the Private Securities Litigation Reform Act of 1995
regarding, among other things: future operating and financial
performance, product development, market position and business
strategy. The reader is cautioned not to rely on these
forward-looking statements. These statements are based on current
expectations of future events. If underlying assumptions prove
inaccurate or known or unknown risks or uncertainties materialize,
actual results could vary materially from the expectations and
projections of Johnson & Johnson. Risks and uncertainties
include, but are not limited to: economic factors, such as interest
rate and currency exchange rate fluctuations; competition,
including technological advances, new products and patents attained
by competitors; challenges inherent in new product research and
development, including uncertainty of clinical success and
obtaining regulatory approvals; uncertainty of commercial success
for new and existing products; challenges to patents; the impact of
patent expirations; the ability of the Company to successfully
execute strategic plans; the impact of business combinations and
divestitures; manufacturing difficulties or delays, internally or
within the supply chain; product efficacy or safety concerns
resulting in product recalls or regulatory action; significant
adverse litigation or government action, including related to
product liability claims; changes to applicable laws and
regulations, including tax laws and global healthcare reforms;
trends toward healthcare cost containment; changes in behavior and
spending patterns of purchasers of healthcare products and
services; financial instability of international economies and
legal systems and sovereign risk; increased scrutiny of the
healthcare industry by government agencies; the Company's ability
to satisfy the necessary conditions to consummate the separation of
the Company's Consumer Health business on a timely basis or at all;
the Company's ability to successfully separate the Company's
Consumer Health business and realize the anticipated benefits from
the separation; the New Consumer Health Company's ability to
succeed as a standalone publicly traded company; and risks related
to the impact of the COVID-19 global pandemic, such as the scope
and duration of the outbreak, government actions and restrictive
measures implemented in response, material delays and cancellations
of medical procedures, supply chain disruptions and other impacts
to the business, or on the Company's ability to execute business
continuity plans as a result of the COVID-19 pandemic. A further
list and descriptions of these risks, uncertainties and other
factors can be found in Johnson & Johnson's Annual Report on
Form 10-K for the fiscal year ended January
2, 2022, including in the sections captioned "Cautionary
Note Regarding Forward-Looking Statements" and "Item 1A. Risk
Factors," and in Johnson & Johnson's subsequent Quarterly
Reports on Form 10-Q and other filings with the Securities and
Exchange Commission. Copies of these filings are available online
at www.sec.gov, www.jnj.com or on request from Johnson &
Johnson. Any forward looking statement made in this release speaks
only as of the date of this release. Johnson & Johnson does not
undertake to update any forward-looking statement as a result of
new information or future events or developments.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/johnson--johnson-releases-2021-health-for-humanity-report-highlighting-performance-on-esg-priorities-and-progress-against-public-commitments-301563567.html
SOURCE Johnson & Johnson